ALVENTA PHARMA LIMITED

VILL. KISHANPURA, TEHSIL BADDI- NALAGARH ROAD, DISTT.- SOLAN (H.P) 174101

Quality Control Department

CERTIFICATE OF ANALYSIS (FINISHED PRODUCT)

Product Name	Aone 1 g	**A.R. No.**	FG/C/25A0007
Generic Name	Ceftriaxone Injection IP 1 g	**Sample Quantity**	65 Vials
Batch No.:	ACD50304	**Sample Received on**	20/03/2025
Batch Size:	0.50 Lac	**Analysis Date**	20/03/2025
Mfg. Date.	03/2025	**Release Date**	03/04/2025
Exp. Date	02/2027	**Page No.:**	Page 1 of 2

Sr. No.	Test Parameter	Acceptance Criteria	Result
1.	**Description**	A white or almost white powder filled in a transparent 10 ml molded glass vial sealed with rubber stopper blue coloured flip off having aluminium seal.	White powder filled in a transparent 10 ml molded glass vial sealed with rubber stopper blue coloured flip off having aluminium seal.
2.	**Identification:**		
	a) **By IR**	The IR Spectrum obtained with test should be concordant with that spectrum obtained from the Ceftriaxone Sodium WS/RS or with the reference spectrum of Ceftriaxone Sodium.	Complies
	b) **By HPLC**	In the assay, the principal peak in the chromatogram obtained with the test solution should corresponds to the peak in the chromatogram obtained with the reference solution (a).	Complies
	c) **By Chemically**	It gives reaction A of Sodium Salts: A dense white precipitate should be formed.	Complies
3.	**Average filled weight**	± 7.5% of Target filled weight.	1118.50 mg
4.	**Uniformity of filled weight**	± 10% of its average filled weight.	Min: 1087.87 mg ; Max: 1144.10 mg -2.74% ; +2.29%
5.	**Clarity of Solution**	Solid should dissolve completely when, leaving no visible residue as undissolved matter.	Solid dissolve completely when, leaving no visible residue as undissolved matter.
6.	**Appearance of Solution**	A Solution is clear and not more intense than reference solution BYS5 or YS5.	A Solution is clear and not more intense than reference solution BYS5
7.	**pH**	Between 6.0 to 8.0, determine in a 10 % w/v solution.	7.16
8.	**Water**	NMT 11.0%w/w	9.76 %w/w
9.	**Particulate matter**	The Sample Solution should be clear and free from any visible particles when examine visually against black background.	The Sample Solution is clear and free from any visible particles.
10.	**Bacterial Endotoxins Tests**	NMT 0.20 EU/mg of Ceftriaxone	Less than 0.20 EU/mg

Particulars	Prepared By	Checked By	Approved By
Name	Praveen Kumar	Amrit Kumar Roy	Kuljeet Kaur
Designation	Executive	Executive	Head QC
Signature			
Date	03/04/2025	03/04/2025	03/04/2025

ALVENTA PHARMA LIMITED

VILL. KISHANPURA, TEHSIL BADDI- NALAGARH ROAD, DISTT.- SOLAN (H.P) 174101

Quality Control Department

CERTIFICATE OF ANALYSIS (FINISHED PRODUCT)

Product Name	Aone 1 g	**A.R. No.**	FG/C/25A0007
Generic Name	Ceftriaxone Injection IP 1 g	**Sample Quantity**	65 Vials
Batch No.:	ACD50304	**Sample Received on**	20/03/2025
Batch Size:	0.50 Lac	**Analysis Date**	20/03/2025
Mfg. Date.	03/2025	**Release Date**	03/04/2025
Exp. Date	02/2027	**Page No.:**	Page 2 of 2

11.	**Sterility**	Should be sterile		Sterile	
12.	**Related Substances:**				
	Area of any secondary Peak	Not more than 1.0%		Not Detected	
	Sum of the areas of all the secondary Peaks	Not more than 5.0%		Not Detected	
13.	**Assay:**				
	Each Vial contains:	**Claim**	**Limit**	**mg**	**%**
	Sterile Ceftriaxone Sodium IP eq. to Ceftriaxone	**1000 mg**	Between 90.0 % to 115.0 % of stated amount of Ceftriaxone.	996.52 mg	99.65%

Remarks: The above test parameters are complies/ ~~not complies~~ as per IP/~~BP~~/USP & In-House Specification.

Particulars	**Prepared By**	**Checked By**	**Approved By**
Name	Praveen Kumar	Aulkit Kumar Thakur	Kuljeet Kaur
Designation	Executive	Executive	Head QC
Signature			
Date	03/04/2025	03/04/2025	03/04/2025